Addition Therapeutics is working on a genetic medicine that would turn a patient’s liver cells into little factories to permanently pump out their own weight loss drugs, the startup told Endpoints News in an exclusive interview.
April 24, 2026 10:00 AM EDTUpdated April 25, 10:10 AM
Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.
As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for both…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Editorial: Evidence is piling up that GLP-1 drugs can treat addiction. We must learn from the way that obesity has been…
Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the booming…
I’m a dietitian - this is why weight-loss jabs won’t work for everyone
